GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Faes Farma SA (LTS:0K9H) » Definitions » LT-Debt-to-Total-Asset

Faes Farma (LTS:0K9H) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Faes Farma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Faes Farma's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Faes Farma's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Jun. 2024 (0.00). It may suggest that Faes Farma is progressively becoming more dependent on debt to grow their business.


Faes Farma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Faes Farma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faes Farma LT-Debt-to-Total-Asset Chart

Faes Farma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - - 0.01 0.01

Faes Farma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 0.01 - -

Faes Farma LT-Debt-to-Total-Asset Calculation

Faes Farma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=4.373/776.029
=0.01

Faes Farma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=3.635/837.531
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faes Farma  (LTS:0K9H) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Faes Farma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Faes Farma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Faes Farma Business Description

Traded in Other Exchanges
Address
Maximo Aguirre, 14, Leioa, Vizcaya, ESP, 48940
Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Faes Farma Headlines

No Headlines